Zoetis Inc
ZTS127.170USD
+0.320+0.25%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
56.14BMarket Cap
21.41P/E TTM
More Details of Zoetis Inc Company
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Zoetis Inc Info
Ticker SymbolZTS
Company nameZoetis Inc
IPO dateFeb 01, 2013
CEOPeck (Kristin C)
Number of employees13800
Security typeOrdinary Share
Fiscal year-endFeb 01
Address10 Sylvan Way
CityPARSIPPANY
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code07054
Phone19738227000
Websitehttps://www.zoetis.com/
Ticker SymbolZTS
IPO dateFeb 01, 2013
CEOPeck (Kristin C)
Company Executives of Zoetis Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
2.82K
+961.00%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
2.59K
+418.00%
Mr. Keith Sarbaugh
Mr. Keith Sarbaugh
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
2.04K
+990.00%
Mr. Nicholas (Nick) Ashton
Mr. Nicholas (Nick) Ashton
Executive Vice President, President - Global Manufacturing and Supply
Executive Vice President, President - Global Manufacturing and Supply
1.09K
+448.00%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+18.00%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+1843.00%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+24.00%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+397.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
Other
380.00M
15.83%
By RegionUSD
Name
Revenue
Proportion
United States
1.32B
55.08%
Other emerging markets
228.00M
9.50%
Other Developed
164.00M
6.83%
Brazil
100.00M
4.17%
Australia
87.00M
3.62%
Other
499.00M
20.79%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Parasiticides
564.00M
23.50%
Vaccines
496.00M
20.67%
Dermatology
472.00M
19.67%
Anti-infectives
284.00M
11.83%
Pain and sedation
204.00M
8.50%
Other
380.00M
15.83%
Shareholding Stats
Updated: Sat, Jan 10
Updated: Sat, Jan 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Other
73.17%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.84%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Other
73.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.16%
Investment Advisor/Hedge Fund
32.07%
Research Firm
4.42%
Insurance Company
3.92%
Bank and Trust
2.63%
Pension Fund
2.55%
Hedge Fund
1.56%
Sovereign Wealth Fund
1.25%
Family Office
0.15%
Other
2.30%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
3273
437.10M
99.18%
-8.45M
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
2023Q3
2966
434.04M
94.28%
-3.00M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
47.78M
10.84%
+5.68M
+13.48%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
22.80M
5.17%
+144.71K
+0.64%
Sep 30, 2025
State Street Investment Management (US)
19.65M
4.46%
-89.97K
-0.46%
Sep 30, 2025
State Farm Insurance Companies
16.87M
3.83%
+21.40K
+0.13%
Sep 30, 2025
Geode Capital Management, L.L.C.
11.14M
2.53%
+57.14K
+0.52%
Sep 30, 2025
Wellington Management Company, LLP
8.54M
1.94%
-348.26K
-3.92%
Sep 30, 2025
Polen Capital Management, LLC
7.52M
1.71%
-904.12K
-10.74%
Sep 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
7.48M
1.7%
+722.07K
+10.69%
Sep 30, 2025
Wells Fargo Advisors
5.64M
1.28%
-193.47K
-3.32%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.18%
+131.36K
+2.60%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ProShares Pet Care ETF
9.4%
VanEck Pharmaceutical ETF
9.02%
VanEck Agribusiness ETF
7.81%
iShares U.S. Pharmaceuticals ETF
4.26%
Honeytree US Equity ETF
3.86%
First Trust NASDAQ Pharmaceuticals ETF
3.58%
Polen Capital Global Growth ETF
3.35%
State Street SPDR S&P Pharmaceuticals ETF
2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
2.47%
Themes US R&D Champions ETF
1.96%
View more
ProShares Pet Care ETF
Proportion9.4%
VanEck Pharmaceutical ETF
Proportion9.02%
VanEck Agribusiness ETF
Proportion7.81%
iShares U.S. Pharmaceuticals ETF
Proportion4.26%
Honeytree US Equity ETF
Proportion3.86%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.58%
Polen Capital Global Growth ETF
Proportion3.35%
State Street SPDR S&P Pharmaceuticals ETF
Proportion2.51%
AAM Sawgrass US Large Cap Quality Growth ETF
Proportion2.47%
Themes US R&D Champions ETF
Proportion1.96%
Dividend
A total of
2.56B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 11, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.53 paid on Mar 03, 2026 going ex on Jan 20, 2026
Jan 20, 2026
Mar 03, 2026
Jan 20, 2026
Oct 09, 2025
ZTS.NB Final Cash Dividend of gross USD 0.5 paid on Dec 02, 2025 going ex on Oct 31, 2025
Oct 31, 2025
Dec 02, 2025
Oct 31, 2025
May 21, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Sep 03, 2025 going ex on Jul 18, 2025
Jul 18, 2025
Sep 03, 2025
Jul 18, 2025
Feb 06, 2025
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Jun 03, 2025 going ex on Apr 21, 2025
Apr 21, 2025
Jun 03, 2025
Apr 21, 2025
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
Oct 12, 2023
ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023
Nov 01, 2023
Dec 01, 2023
Oct 31, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zoetis Inc?
The top five shareholders of Zoetis Inc are:
The Vanguard Group, Inc. holds 47.78M shares, accounting for 10.84% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 22.80M shares, accounting for 5.17% of the total shares.
State Street Investment Management (US) holds 19.65M shares, accounting for 4.46% of the total shares.
State Farm Insurance Companies holds 16.87M shares, accounting for 3.83% of the total shares.
Geode Capital Management, L.L.C. holds 11.14M shares, accounting for 2.53% of the total shares.
The Vanguard Group, Inc. holds 47.78M shares, accounting for 10.84% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 22.80M shares, accounting for 5.17% of the total shares.
State Street Investment Management (US) holds 19.65M shares, accounting for 4.46% of the total shares.
State Farm Insurance Companies holds 16.87M shares, accounting for 3.83% of the total shares.
Geode Capital Management, L.L.C. holds 11.14M shares, accounting for 2.53% of the total shares.
What are the top three shareholder types of Zoetis Inc?
The top three shareholder types of Zoetis Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Zoetis Inc (ZTS)?
As of 2025Q4, 3273 institutions hold shares of Zoetis Inc, with a combined market value of approximately 437.10M, accounting for 99.18% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.89%.
What is the biggest source of revenue for Zoetis Inc?
In FY2025Q3, the Parasiticides business generated the highest revenue for Zoetis Inc, amounting to 564.00M and accounting for 23.50% of total revenue.
